Please use this identifier to cite or link to this item:
http://hdl.handle.net/11054/1950
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Burrell, A. | en_US |
dc.contributor | Neto, A. | en_US |
dc.contributor | Broadley, T. | en_US |
dc.contributor | Trapani, T. | en_US |
dc.contributor | Begum, H. | en_US |
dc.contributor | Campbell, L. | en_US |
dc.contributor | Cheng, A. | en_US |
dc.contributor | Cheung, W. | en_US |
dc.contributor | Cooper, J. | en_US |
dc.contributor | Erickson, S. | en_US |
dc.contributor | French, C. | en_US |
dc.contributor | Kaldor, J. | en_US |
dc.contributor | Litton, E. | en_US |
dc.contributor | Murthy, S. | en_US |
dc.contributor | McAllister, R. | en_US |
dc.contributor | Nichol, A. | en_US |
dc.contributor | Palermo, A. | en_US |
dc.contributor | Plummer, M. | en_US |
dc.contributor | Ramanan, M. | en_US |
dc.contributor | Reddi, B. | en_US |
dc.contributor | Reynolds, C. | en_US |
dc.contributor | Webb, S. | en_US |
dc.contributor | Udy, A. | en_US |
dc.date.accessioned | 2022-06-01T23:37:52Z | - |
dc.date.available | 2022-06-01T23:37:52Z | - |
dc.date.issued | 2021 | - |
dc.identifier.govdoc | 01874 | en_US |
dc.identifier.uri | http://hdl.handle.net/11054/1950 | - |
dc.description | Includes data from BHS | en_US |
dc.description.abstract | Objective: To report longitudinal differences in baseline characteristics, treatment, and outcomes in patients with coronavirus disease 2019 (COVID-19) admitted to intensive care units (ICUs) between the first and second waves of COVID-19 in Australia. <br /><br /> Design, setting and participants: SPRINT-SARI Australia is a multicentre, inception cohort study enrolling adult patients with COVID-19 admitted to participating ICUs. The first wave of COVID-19 was from 27 February to 30 June 2020, and the second wave was from 1 July to 22 October 2020. <br /><br /> Results: A total of 461 patients were recruited in 53 ICUs across Australia; a higher number were admitted to the ICU during the second wave compared with the first: 255 (55.3%) versus 206 (44.7%). Patients admitted to the ICU in the second wave were younger (58.0 v 64.0 years; P = 0.001) and less commonly male (68.9% v 60.0%; P = 0.045), although Acute Physiology and Chronic Health Evaluation (APACHE) II scores were similar (14 v 14; P = 0.998). High flow oxygen use (75.2% v 43.4%; P < 0.001) and noninvasive ventilation (16.5% v 7.1%; P = 0.002) were more common in the second wave, as was steroid use (95.0% v 30.3%; P < 0.001). ICU length of stay was shorter (6.0 v 8.4 days; P = 0.003). In-hospital mortality was similar (12.2% v 14.6%; P = 0.452), but observed mortality decreased over time and patients were more likely to be discharged alive earlier in their ICU admission (hazard ratio, 1.43; 95% CI, 1.13-1.79; P = 0.002). <br /><br /> Conclusion: During the second wave of COVID-19 in Australia, ICU length of stay and observed mortality decreased over time. Multiple factors were associated with this, including changes in clinical management, the adoption of new evidence-based treatments, and changes in patient demographic characteristics but not illness severity. | en_US |
dc.description.provenance | Submitted by Gemma Siemensma (gemmas@bhs.org.au) on 2022-05-04T06:51:24Z No. of bitstreams: 0 | en |
dc.description.provenance | Approved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2022-06-01T23:37:52Z (GMT) No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2022-06-01T23:37:52Z (GMT). No. of bitstreams: 0 Previous issue date: 2021 | en |
dc.title | Comparison of baseline characteristics, treatment and clinical outcomes of critically ill Covid-19 patients admitted in the first and second waves in Australia. | en_US |
dc.type | Journal Article | en_US |
dc.type.specified | Article | en_US |
dc.contributor.corpauthor | SPRINT SARI Australia Investigators | en_US |
dc.bibliographicCitation.title | Critical Care and Resuscitation | en_US |
dc.bibliographicCitation.volume | 23 | en_US |
dc.bibliographicCitation.issue | 3 | en_US |
dc.bibliographicCitation.stpage | 308 | en_US |
dc.bibliographicCitation.endpage | 319 | en_US |
dc.subject.healththesaurus | PUBLIC HEALTH EVALUATION | en_US |
dc.subject.healththesaurus | COVID-19 (DISEASE) | en_US |
dc.subject.healththesaurus | CLINICS-MANAGEMENT | en_US |
dc.subject.healththesaurus | EPIDEMICS | en_US |
dc.subject.healththesaurus | POLYMERASE CHAIN REACTION | en_US |
dc.subject.healththesaurus | AUSTRALIA | en_US |
dc.identifier.doi | https://doi.org/10.51893/2021.3.oa8 | en_US |
Appears in Collections: | Research Output |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.